"Abbott shares have declined 19.22% year-to-date and 6.79% over the past month, trading beneath both its 50-day and 200-day moving averages."
"The FreeStyle Libre drives the bull thesis, with CGM sales hitting $2B in Q4 2025, up 15% YoY, and expected growth from retail expansion."
"Management guided for 6.5%-7.5% organic sales growth and $5.55-$5.80 adjusted EPS in 2026, indicating roughly 10% growth at the midpoint."
"Key risks include Diagnostics pressure from COVID-19 testing collapse and Nutrition softness, which saw an -8.9% revenue decline in Q4 2025."
Abbott Laboratories has experienced a significant decline in stock price, trading near its 52-week low. The company reported mixed Q4 2025 earnings, with adjusted EPS beating estimates but revenue missing consensus. The FreeStyle Libre product line is a key growth driver, with strong sales and expected growth from a recent acquisition. Analyst targets suggest potential upside, but risks include declining COVID-19 testing revenues and challenges in the Nutrition segment.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]